Results Presentation
1Q FY Ending March 2023
Win-Partners Co., Ltd. (3183)

1Q results to June 2022

Highlights⚫ Number of cases in major segments increased YoY⚫ Negative impact from the revision of reimbursement
prices was more than offset by YoY volume increase
and sales expansion in the Medical Equipment
Division⚫ Gross profit margins lowered partly because ofongoing price negotiations with customers after therevision of reimbursement prices (about 47% agreed
at the end of June)⚫ Increased sales and a moderate increase in SGA
enabled operating profit to grow YoY
3Consolidated results summary（¥ mil.）1Q toJun 2021

Jun 2022

YoY(%)

Sales

15,436+8.5－－

Operating profit

535

Recurring profit

536

Net profit

365

EPS (yen)

12.72

16,744
557
558
400
14.11

BPS (yen)714.99743.58+4.2+3.9+9.8

4

Highlights (sales)
YoY+8.5%(¥ mil.)16,744
15,436

1Q to Jun 2021

1Q to Jun 2022⚫

Number of cases in major segments increased YoY⚫

Sales increased YoY in all segments except for PCI⚫

Negative impact from the revision of reimbursementprices was more than offset by YoY volume increase
and sales expansion in the Medical Equipment Division5Sales breakdown by segment (YoY)
SegmentSales（¥ mil.）YoY growth (%)
VolumeValue% of sales(%)

Percutaneous coronary intervention (PCI)

4,159

+3.1

-0.8

24.8

Cardiac rhythm segment (CRS)

4,446+4.6+5.5

26.6

Cardiac vascular segment (CVS)2,602+9.1+11.2

15.5

Percutaneous peripheral intervention (PPI)986+7.1+6.2

5.9

Neurovascular728-0.1+3.4

4.3

Diabetes mellitus segment (DMS)792-+23.0

4.7

Medical equipment

1,643-+49.2

9.8

Others1,384-+5.7

8.3

16,744-+8.5

100.0

Total

6

Highlights (operating profit)
YoY+4.2%(¥ mil.)535557

1Q to Jun 2021

1Q to Jun 2022

⚫ Gross profit margin 11.9% (-0.5 pp YoY)

- Gross profit margins lowered from a year earlier partly because of ongoing pricenegotiations with customers and suppliers after the revision of reimbursement
prices⚫ SGA +4.1% YoY- Labor cost and other expenses increased YoY (+1.8% YoY and +10.3% respectively)- Number of employees: 557 (Jun 2021) → 565 (Jun 2022)
7

M&A of TOSAY Medical✔Medical device distributor based in Iwate Prefecture✔ 100% of shares are owned by TESCO (since August 2022)(Impact on earnings is under assessment)

TOSAY Medical’s figures
Oct/2021 (¥bn)
Sales
4.5
OP
0.1
Total assets
2.2
Net assets
0.9

As a result, TESCO
has expanded its
business territory
into 5 out of 6
prefectures in theTohoku region (with8 sales bases in total)
TESCO/MCI sales offices

TOSEI Medical sales office8

Transformation of TSE & sustainability⚫ Transition to the TSE Prime market⚫ Expression of support for therecommendations of TCFD andparticipation in TCFD Consortium⚫ Sustainability
Promotion system, materiality and information disclosure in line with TCFD
recommendations are disclosed on website at

http://www.win-partners.co.jp/en/company/sustainability/system.html
9References

Sales impact from the reimbursement
price revision in April
Assumedimpact (%)

Segment
Percutaneous Coronary Intervention (PCI)-7.0

Cardiac Rhythm Segment (CRS)-4.4

Cardiac Vascular Segment (CVS)-0.3

Percutaneous Peripheral Intervension (PPI)-3.9

Brain Surgery-0.7

Others

-0.3

Total

-3.3
Calculated based on the actual sales volume and product mix for FY ended March 2022

11

Reimbursement prices ofmajor products
Segment

PCI

Items
PTCA balloon catheter
Drug eluting stent (DES)PPI
Neurovascular

2022

Change (%)

32
136
72

720
2,950
3,990
3,120
124
649
1,320
1,110

593
2,820
3,260
3,120
117
649
1,320
1,110

- 9.9
- 15.5- 9.7- 17.6- 4.4- 18.3
0.0
- 5.6
0.0
0.0
0.0

Hea rt va l ve for tra ns ca theter a orti c va l ve i mpl a nta ti on(TAVI) (ba l l oon-expa nda bl e)

4,510

4,510

0.0

Heart valve for TAVI (self-expandable)
PTA balloon catheter
Peripheral vascular stent
Peripheral drug eluting stent (DES)
Embolic coil (electric type)
Thrombectomy catheter (self-expandable)

3,740
55
174
233
118
386

3,74050
* 171
233
117
386

0.0
- 7.8
- 1.7
0.0
- 0.8
0.0

Pacemaker
Implantable cardioveter defibrillator (ICD)

CVS202035161
80

Intravascular ultrasound (IVUS) catheter

CRS

Reimbursement prices (¥000)

Cardiac resychronization therapy defibrillator (CRTD)

Subcutaneous implantable defibrillator (S-ICD）
Ablation catheter
Cardiac cryoablation catheter
Stent graft (abdomen）
Open stent graft* Transitional period (1/4/2022 to 31/12/2022: ¥171,000 1/1/2023 to 31/3/2023: ¥166,000 1/4/2023 onward: ¥160,000)
12

Disclaimer
This material was prepared based on the information available and the views held at the time it was made. Statements in thismaterial that are not historical facts, including but not limited to plans, forecasts and strategies are “forward-looking statements.”
Forward-looking statements are by their nature subject to various risks and uncertainties, including but not limited to a decline ingeneral economic conditions, general market conditions, technological developments, changes in customer demand for products
and services, increased competition, and other important factors, each of which may cause actual results and future developments
to differ materially from those expressed or implied in any forward-looking statement.
With the passage of time, the information in this material (including but not limited to forward-looking statements) could besuperseded or cease to be accurate. WIN-Partners Co., Ltd. disclaims any obligation or responsibility to update, revise, orsupplement any forward-looking statement or other information in any material or generally to any extent. The utilization of orreliance on the information in this material is at your own risk.

Contact
WIN-Partners Co., Ltd.
Investor Relations
Phone: +81-3-3548-0790
http://www.win-partners.co.jp